Observational studyInvestigational new drugs2025

Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.

Hiroyasu Kaneda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.